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Yersinia pestis is the causative agent of
plague, a disease transmitted from rodent to
rodent by the bites of fleas. Bubonic plague, the
most common form of the disease, occurs through
rodent-to-human transmission by infected fleas
of peridomestic animals (rats, cats) or wild
rodents. Pneumonic plague, a less frequent but
highly severe form of the disease, is transmitted
from human to human by infected droplets
spread by a patient with lung infection (1).
Public health measures and effective antibi-
otic treatments have led to a drastic decrease in
plague worldwide. However, the disease is not
eradicated. Endemic plague foci persist in Africa,
Asia, and North and South America. During the
last 15 years (1982 to 1996), 23,904 human
plague cases and 2,105 deaths were reported to
the World Health Organization by 24 countries
(2). The most affected countries are Madagascar
and Tanzania in Africa, Vietnam in Asia, and
Peru in the Americas. Since the early 1990s, a
steadily increasing trend in human plague cases
has been reported to the World Health
Organization. This trend is partly attributable to
epidemics in places where human plague had
disappeared for several decades and has led the
World Health Organization to categorize plague
as a reemerging disease (3). The reasons for
plague’s reemergence are not clear but may be
partly attributable to inadequate surveillance.
Streptomycin, chloramphenicol, and tetracy-
cline, alone or in combination, are the reference
drugs to treat plague, whereas tetracycline or
sulfonamides are recommended for prophylaxis
(4). Classically, Y. pestis isolates are uniformly
susceptible to all  antibiotics active against gram-
negative bacteria (5-7). Recently, high-level
resistance to multiple antibiotics, including those
recommended for plague prophylaxis and
therapy, was observed in a clinical isolate of
Y. pestis in Madagascar (8).
We report high-level resistance to streptomy-
cin (the reference antibiotic for plague treatment)
in a second strain of Y. pestis isolated in
Madagascar. The resistance genes were carried
by a plasmid that could conjugate at high
frequencies to other Y. pestis isolates.
Materials and Methods
Patient and Strains
In our study of the second resistant Y. pestis
isolate,  Y. pestis 16/95, we used the bacterial
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Table 1. Bacterial strain used in study of resistant Yersinia pestis isolate 16/95
Strain Characteristics and plasmid contenta Source or reference
Y. pestis
16/95 pFra, pPla, pYV, pIP1203 Tra+b Smc Wild strain
6/69 pFra, pPla, pYV Wild strain
6/69cN Nald, pFra, pPla Spontaneous Nal mutant of pYV cured 6/69
6/69cNR Nal, Rife, pFra, pPla Spontaneous Rif mutant of 6/69cN
6/69cN(pIP1203) Nal, pFra, pPla, pIP1203 Tra+ Sm Transconjugant 16/95 x 6/69cN
Y. pseudotuberculosis
IP32790 pYV Wild strain
IP32790cN Nal Spontaneous Nal mutant of pYV cured P32790
IP32790cN(pIP1203) Nal, pIP1203 Tra+ Sm Transconjugant 16/95 x IP32790cN
Y. enterocolitica
IP864 pYV Wild strain
IP864cN Nal Spontaneous Nal mutant of pYV cured IP864
Escherichia coli
C600R thr leuB6 thi-1 lacY supE rpoB Spontaneous Rif mutant of C600, Bachmann (9)
JM109 hsdR- supE gyrA Yanisch-Perron et al. (10)
K802N hsdR- hsdM+ gal- met- supE gyrA Wood (11)
K802N(pIP1203) pIP1203 Tra+ Sm Transconjugant 16/95 x K802N
aPlasmid content = pFRa, pPla, and pYV are the endogenous plasmids of Y. pestis (12).
bTra+ = self-transferable.
cSm = streptomycin resistance.
dNal = nalidixic acid resistance.
eRif = rifampicin resistance.
strains listed in Table 1. The isolate, biotype
Orientalis and ribotype Q, was obtained in 1995
in the Ampitana District of Madagascar from the
axillary bubo puncture of a 14-year-old boy before
antibiotic treatment. No recent history of travel
outside the village was noted. Dead rats were
found inside his house before the onset of the
disease. The patient was treated with twice a day
intramuscular injections of streptomycin (2 g per
day for 4 days) and oral trimethoprim-sulfamethox-
azole (2 g per day for 10 days) and recovered.
Media and Resistance Studies
Brain-heart infusion broth and agar (Difco
Laboratories, Detroit, MI) were used. The MICs
of antibiotics were determined on Mueller-
Hinton agar (Sanofi Diagnostics Pasteur, Marnes-
la-Coquette, France). The cultures were incu-
bated for 18 hours at 37°C for Escherichia coli
and for 48 hours at 28°C for Yersinia strains.
Aminoglycoside-modifying enzymes were as-
sayed by the phosphocellulose paper-binding
technique (13) in supernatants (centrifuged at
100,000 x g) after ultrasonic bacterial disintegra-
tion. Mating on filters was performed as
described previously (8). Transfer frequencies
were expressed as the number of transconjugants
per donor colony-forming unit after the mating
period. Antibiotic concentrations for selection
were 100 mg/L for ampicillin, 50 mg/L for
nalidixic acid, 100 mg/L for rifampicin, and 25
mg/L for streptomycin.
Nucleic Acid Techniques
Isolation of plasmid DNA, cleavage of
restriction fragments, and purification of DNA
fragments from agarose type VII (Sigma
Chemical Co., St. Louis, MO) were performed as
described elsewhere (14). Pulsed-field gel
electrophoresis was performed for 18 hours with
a CHEF-DRIII apparatus (Bio-Rad Laboratories,
Richmond, CA), by using an electric field of 6 V/
cm and an angle of 120°. Initial and final pulse
times were 0.1 second and 6 seconds, respectively.
Migration of the DNA fragments was performed
in 0.5X Tris-Borate-EDTA buffer in a 0.9%
agarose gel at 17°C. DNA sequencing reactions
were performed with a Taq BigDye Terminator
cycle sequencing kit (Applied Biosystems, Foster
City, CA) in a Perkin-Elmer 9700 thermocycler.
The samples were loaded onto 4% polyacrylamide
gels and electrophoresed on a Model ABI PRISM
377 automatic DNA sequencer (Perkin-Elmer,
Norwalk, CT). The nucleotide sequence of the45 Vol. 7, No. 1, January–February 2001 Emerging Infectious Diseases
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Table 2. Conjugative transfer of pIP1203
Donor Recipient Frequency of transfer
Yersinia pestis 16/95 Y. pestis 6/69cN 3 x 10-1
Y. pseudotuberculosis IP32790cN 1 x 100
Y. enterocolitica IP864cN  <10-7
E. coli  K802N 2 x 10-5
Y. pestis 6/69cN (pIP1203) Y. pestis 6/69cNR 2 x 10-1
Y. pseudotuberculosis IP32790cNR 5 x 10-1
Y. pseudotuberculosis IP32790cN(pIP1203) Y. pestis 6/69cNR 3 x 10-2
Y. pseudotuberculosis IP32790cNR 2 x 10-2
E. coli  C600R  <10-7
Escherichia coli K802N (pIP1203) Y. pestis 6/69cNR 6 x 10-2
Y. pseudotuberculosis IP32790cN 1 x 10-3
E. coli C600R 1 x 10-5
Figure 1. Analysis of plasmid pIP1203. A) Agarose-gel
electrophoresis of EcoRV-digested plasmid DNA from
representative Yersinia pestis strain 6/69 (1) and from
streptomycin-resistant strain 16/95 (2). B) Pulsed-
field gel electrophoresis of pIP1203 DNA extracted
from  Escherichia coli K802N transconjugant and
digested by EcoRV (1), EcoRI+EcoRV (2), and EcoRI
(3). The arrow indicates the extra large-size DNA
fragment in strain 16/95. The size of the molecular
weight markers in kilobases is indicated at the left of
the gels.
strA and strB genes and of flanking regions from
pIP1203 has been deposited in the EMBL data
bank under accession number AJ249779.
Results
Streptomycin Resistance in Y. pestis 16/95
Disk-agar diffusion tests showed that
Y. pestis 16/95 was resistant to streptomycin but
remained susceptible to spectinomycin and other
antibiotics, including those recommended for
plague therapy (chloramphenicol and tetracy-
cline) and prophylaxis (sulfonamides and tetra-
cycline) (4). The MICs of streptomycin and
spectinomycin for this strain were 1,024 mg/L
and 16 mg/L, respectively. High-level resistance
was due to the presence of a streptomycin
phosphotransferase activity. No adenylyl trans-
ferase activity was found (data not shown).
Transfer of Streptomycin Resistance
to Other Bacterial Species
Attempts were made to transfer streptomy-
cin resistance from Y. pestis 16/95 by conjugation
to recipient strains (MIC < 8 mg/L) (Table 2).
Transfer occurred at high frequencies (3 x 10-1
per donor CFU) to Y. pestis (MIC = 1,024 mg/L)
and Y. pseudotuberculosis (MIC = 256 mg/L) and
at lower frequencies to E. coli (MIC = 128 mg/L);
transfer to Y.  enterocolitica was not detected.
Retransfer of streptomycin resistance from
Y. pestis and Y. pseudotuberculosis transconju-
gants to Y. pestis and Y. pseudotuberculosis also
occurred at high frequencies (3 x 10-2) and was
less efficient when E. coli was used as the
recipient strain.
Characterization of Plasmid pIP1203
Plasmid DNA was extracted from Y. pestis 6/
69 and 16/95 and digested by EcoRV (Figure 1A).46 Emerging Infectious Diseases Vol. 7, No. 1, January–February 2001
Research
The restriction fragments in strain 6/69 correspond
to those of the three Y. pestis resident plasmids,
pPla, pYV, and pFra (12). Comparison of the
restriction profiles of strains 6/69 and 16/95
revealed that the latter contained at least one
extra large-size EcoRV fragment corresponding
to an additional plasmid, designated pIP1203.
Upon transfer to E. coli, the size of pIP1203 was
estimated (after single and double digestion with
EcoRI and EcoRV) to be approximately 40 kb
(Figure 1B).
Plasmid pIP1203 was stable after 100
generations in Y. pestis 16/95 and E. coli K802N
(frequency of loss <0.25%). In experiments
performed by reciprocal conjugation to assess the
incompatibility group, pIP1203 exhibited strong
incompatibility with plasmid RP4 (data not
shown), which belongs to the IncP group. No
incompatibility with prototype plasmids of
incompatibility groups Inc FI, FII, I1, I2, N, 6-C,
7-M, 10-B-O, J, T, and W was observed (15).
Characterization of the
Streptomycin-Resistance Genes
To clone the streptomycin-resistant determi-
nant, DNA from plasmids pIP1203 and pUC18
was partially digested with Sau3AI and BamHI,
respectively, ligated, and introduced into E. coli
JM109 (MIC of streptomycin = 2 mg/L). The
smallest recombinant plasmid conferring
streptomycin resistance, pAT709, contained an
11-kb insert. The resistance determinant was
subcloned by introducing a 2.7-kb HincII
fragment of the 11-kb insert into pUC18, which
generated pAT710. This recombinant plasmid
conferred high levels of resistance to the new host
(MIC of streptomycin = 512 mg/L) by synthesis of
a streptomycin phosphotransferase. Sequence
determination of the insert in pAT710 revealed
that the base composition of this fragment was
57.5% G+C, much higher than the average G+C
content of the Y. pestis genome (46%) (16). Two
potentially coding sequences of 801 bp and 834 bp
identified in the insert were identical to the strA
and strB genes that encode an aminoglycoside 3"-
O-phosphotransferase [APH(3")-Ib] and a 6-O-
phosphotransferase [APH(6)-Id], respectively
(17). The str genes were originally described in
the small, nonconjugative, broad-host-range
IncQ plasmid RSF1010 (18). They have been
subsequently found as part of transposon
Tn5393 and related elements in phytopathogenic
Erwinia amylovora, Pseudomonas syringae pv.
papulans,  and  Xanthomonas campestris pv.
vesicatoria (19,20).
An 81-bp sequence identical to the inverted
terminal repeat (IR) of Tn5393 was identified
downstream from pIP1203 strA-strB genes
(Figure 2). This IR is always present at the same
position in the various genetic structures that
Figure 2. Genetic organization of the strA-strB genes. Schematic representation of the regions of Tn5393 and
derivatives and of plasmids RSF1010, and pIP1203 carrying the strA and strB genes. IR, inverted repeat; tnpA,
transposase; res, resolution site; tnpR, resolvase; IS1133 and IS6100, insertion sequences; korB and incC, genes
homologous to those involved in regulation and partition of plasmid R751, respectively; oriV, origin of vegetative
replication of R751. Direction of gene transcription is indicated by arrows.47 Vol. 7, No. 1, January–February 2001 Emerging Infectious Diseases
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carry the str genes. Upstream from strA, the
sequence was identical to a portion of the tnpR
resolvase-repressor gene of Tn5393, Tn5393a,
and Tn5393b (20). The identity was interrupted
after 105 bp within the 3'-end of tnpR (Figure 2).
Like Tn5393a, pIP1203 possessed the TAG motif,
which represents a putative insertion target for
IS1133 (20).
The  tnpR-strA-strB-IR region of pIP1203,
which displayed a Tn5393-like organization, was
flanked on both sides by sequences highly similar
to portions of the broad-host-range IncP plasmid
R751 (21). Upstream from the truncated tnpR
gene, there was identity with the 3'-end of the
incC2 and the 5'-end of the korB genes [positions
3396 to 3820 of plasmid R751, numbering
according to GenBank accession number U67194].
Downstream from the IR, identity was found
with a portion of plasmid R751 (positions 9796 to
9947, numbering according to GenBank acces-
sion number U67194), located in the vicinity of
the oriV vegetative origin of replication.
Discussion
Y. pestis strain 16/95, isolated in Madagascar
in 1995 from a human case of bubonic plague,
carried the self-transferable plasmid pIP1203
conferring resistance to streptomycin. The strain
of  Y. pestis 17/95 harboring the multidrug-
resistance conjugative plasmid pIP1202 de-
scribed in 1997 (8) was also isolated in
Madagascar from a human case. However, the
two strains differ in several aspects: they were
isolated in two districts of Madagascar
(Ambalavao and Ampitana) that are 120 km (80
miles) apart; strain 17/95 is of the typical ribotype
B, whereas strain 16/95 is of the newly described,
Madagascar-specific, ribotype Q (22); plasmid
pIP1202 carries multiple antibiotic resistance
genes, belongs to the Inc6-C group, and is 150 kb
in size, whereas pIP1203 carries only the
streptomycin resistance determinants, belongs
to the IncP group, and is 40 kb in size; and
streptomycin resistance is due to adenylylation of
the drug in strain 17/95 and to phosphorylation in
strain 16/95. Therefore, the two resistant
Y. pestis isolated in Madagascar correspond to
distinct strains that have acquired different
conjugative plasmids.
The streptomycin resistance genes in pIP1203
are part of the tnpR-strA-strB-IR cluster
characteristic of the Tn5393 group of transposons.
This portion of the element is inserted in R751, a
broad-host-range plasmid belonging to the IncP
group. The sequences flanking the tnpR-strA-
strB-IR region in pIP1203 are separated by
approximately 6 kb in the original R751 backbone
(21). This organization suggests that insertion of
a Tn5393-like element was associated with
concomitant (or subsequent) loss of a region
involved in the control of plasmid stability.
Despite this deletion, pIP1203 appears to be
highly stable in both Y. pestis and E. coli.
IncP plasmids are promiscuous; therefore,
the original host of pIP1203 remains unknown.
However, since this plasmid was extremely
stable in Y. pestis 16/95, conferred high-level
resistance to streptomycin, and could transfer at
remarkably high frequencies to other strains of
Y. pestis, it is possible that pIP1203 was acquired
a long time ago and is now well adapted to this
bacterial species.
It is not known where genetic transfer of the
resistance plasmid took place. During its flea-
host-flea cycle, Y. pestis may have been in contact
with the donor cell, either in its mammalian host
(rodent or human) or the insect vector. In
mammals, Y. pestis circulates in a usually sterile
milieu (lymphatic vessels, spleen, liver, blood,
and sometimes lungs). Contact with the bacterial
donor and transfer of pIP1203 may have occurred
in the bloodstream at the premortem stage of
infection, when gut bacteria invade the host.
Alternatively, plasmid acquisition may have
taken place in the midgut of the flea, a nonsterile
environment where Y. pestis is most likely to be
in intimate contact with other microorganisms.
From a clinical and public health point of
view, this report is of great concern and indicates
that surveillance of antibiotic resistance in
Y. pestis should become systematic worldwide.
Streptomycin, an inexpensive, easy to use, and
highly effective drug against Y. pestis, represents
the therapy of choice for plague in Madagascar.
Spread of plasmids pIP1202 and pIP1203 among
strains of Y. pestis would render streptomycin
ineffective for plague treatment and could create
economic and therapeutic problems in Madagas-
car and other countries with endemic plague foci.
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